NCT04777760 Surfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS)
| NCT ID | NCT04777760 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
| Condition | Respiratory Distress Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2021-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2021-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In preterm infants with neonatal respiratory distress syndrome (NRDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal mortality. Nowadays, PS is commonly used in newborn infants with respiratory distress, but the incidences of bronchopulmonary dysplasia(BPD) and/or death are inconsistent. The result indicates that not all preterm infants with respiratory distress can be beneficial from PS. In 2017, the international neonatal ARDS (NARDS) collaborative group provides the first consensus definition for NARDS. And whether or not PS being beneficial for preterm infants with NARDS remains unknown.
Eligibility Criteria
Inclusion Criteria: Eligibility requirements for neonates were as follows: * The gestational age is less than 37 weeks and admitted to neonatal intensive care unit(NICU) in 24 h after birth * The neonates will be diagnosed with NRDS or NARDS * The neonates will be at least administrated one dose of surfactant Exclusion Criteria: one of the following criteria will be needed * major congenital anomalies * chromosomal abnormalities * upper respiratory tract abnormalities
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04777760 clinical trial?
This trial is open to participants of all sexes, aged 1 Minute or older, up to 24 Hours, studying Respiratory Distress Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04777760 currently recruiting?
Yes, NCT04777760 is actively recruiting participants. Contact the research team at neuroclong@126.com for enrollment information.
Where is the NCT04777760 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT04777760 clinical trial?
NCT04777760 is sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. The trial plans to enroll 400 participants.